Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI351 DDI with Esomeprazole and Food Effect in Healthy Subjects
NCT05688124Phase 1Completed
- Sponsor
- Innovent Biologics
- Start
- Feb 2023
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fulzerasib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Innovent Biologics. Primary endpoints: Maximum Plasma Concentration at 10 days, Area Under the Curve from Time 0 to Infinity at 10 days and 1 more. Started Feb 2023; status: completed.
02
Drugs
fulzerasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05688124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05688124.